New England Journal of Medicine OCTOBER 04, 2012

Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock (IABP-SHOCK II)

Holger Thiele, Uwe Zeymer, Franz-Josef Neumann, et al.

Bottom Line

In patients with acute myocardial infarction complicated by cardiogenic shock undergoing early revascularization, the routine use of intraaortic balloon counterpulsation (IABP) did not significantly reduce 30-day, 1-year, or 6-year all-cause mortality compared with medical therapy alone.

Key Findings

1. At 30 days, the primary endpoint of all-cause mortality was 39.7% in the IABP group compared to 41.3% in the control group (relative risk 0.96; 95% CI 0.79-1.17; P=0.69).

2. Long-term follow-up at 6 years demonstrated no significant difference in all-cause mortality (66.3% in the IABP group vs. 67.0% in the control group; P=0.98).

3. There were no significant differences between groups in secondary safety outcomes, including major bleeding, peripheral ischemic complications, sepsis, or stroke at either short- or long-term time points.

4. The use of IABP did not improve secondary clinical parameters, including quality of life, re-infarction, or rates of repeat revascularization.

Study Design

Design

RCT

Open-Label

Sample

600

Patients

Duration

30 days (initial), 6 years (long-term)

Median

Setting

Multicenter, Germany

Population Adult patients with acute myocardial infarction complicated by cardiogenic shock scheduled for early revascularization.

Intervention Insertion of an intraaortic balloon pump plus optimal medical therapy.

Comparator Optimal medical therapy alone (no planned IABP).

Outcome All-cause mortality at 30 days.

Study Limitations

• The study was open-label, which may introduce performance and reporting bias, though the primary mortality endpoint is objective.

• The trial was not powered to detect smaller clinical differences, and mortality in the control group was lower than the historically anticipated rates used for the sample size calculation.

• The population included both STEMI and NSTEMI, potentially introducing heterogeneity, although sub-group analyses remained neutral.

• The trial was performed in the modern PCI-era with high rates of prompt revascularization, which may have limited the potential incremental hemodynamic benefit of IABP.

Clinical Significance

The IABP-SHOCK II trial provided definitive evidence that routine IABP support does not provide a survival benefit in patients with cardiogenic shock complicating acute myocardial infarction. Consequently, international clinical guidelines were downgraded, and IABP is no longer recommended as a routine treatment for this condition.

Historical Context

Prior to this trial, IABP had been a class I recommendation in cardiogenic shock based largely on observational registries and small, non-randomized studies. Its use was widespread despite weak evidence. The IABP-SHOCK II results fundamentally shifted the paradigm in cardiac intensive care, moving practice away from routine counterpulsation toward more evidence-based, selective mechanical circulatory support strategies.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

The intraaortic balloon pump (IABP) works through the principle of counterpulsation; how does the timing of balloon inflation and deflation relate to the cardiac cycle to theoretically improve myocardial oxygen supply and demand?

Key Response

The IABP inflates during diastole (immediately after the dicrotic notch) to increase aortic diastolic pressure and coronary artery perfusion (diastolic augmentation). It deflates just before systole (during the R-wave) to create a vacuum effect, reducing afterload and myocardial oxygen demand. Despite this physiological logic, the IABP-SHOCK II trial showed these changes did not translate into a mortality benefit for patients in cardiogenic shock.

Resident

Given the neutral findings of the IABP-SHOCK II trial regarding all-cause mortality, what are the remaining Class II indications for IABP in the context of acute myocardial infarction according to current ACC/AHA or ESC guidelines?

Key Response

While routine use in cardiogenic shock is not recommended (Class III), IABP is still considered for patients with mechanical complications of MI, such as acute mitral regurgitation or ventricular septal rupture (VSR), to provide temporary stabilization as a bridge to definitive surgical repair. It may also be considered in cases of refractory ischemia or as a bridge to more advanced mechanical circulatory support.

Fellow

The IABP-SHOCK II trial predominantly involved IABP insertion after the primary PCI procedure. Does the timing of device initiation (pre-PCI vs. post-PCI) represent a significant confounder, and how does this relate to the concept of 'door-to-unload' in modern mechanical circulatory support?

Key Response

Critics argue that IABP insertion after revascularization may be 'too late' to prevent the systemic inflammatory response and metabolic spiral of shock. The 'door-to-unload' concept suggests that active ventricular unloading (usually with more potent devices like Impella) prior to reperfusion might limit reperfusion injury and infarct size, a hypothesis that IABP-SHOCK II was not specifically designed to test as 86% received the pump after PCI.

Attending

The IABP-SHOCK II trial is often cited as a landmark example of 'medical reversal.' How should this trial's long-term (6-year) follow-up data influence our approach to adopting new, more expensive mechanical circulatory support (MCS) technologies that currently lack high-level RCT evidence?

Key Response

The 6-year follow-up confirmed that even with long-term recovery potential, there was no latent survival benefit for IABP. This serves as a cautionary tale: physiological surrogates (like increased MAP) do not guarantee hard clinical outcomes. It underscores the need for rigorous RCTs for newer devices like Impella (e.g., DanGer Shock) or VA-ECMO (e.g., ECLS-SHOCK) rather than relying on observational data or device manufacturer claims.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

In IABP-SHOCK II, approximately 10% of the control group crossed over to receive IABP therapy. How does this crossover affect the interpretation of the Intention-to-Treat (ITT) analysis, and what alternative statistical frameworks could be employed to estimate the true 'efficacy' of the intervention?

Key Response

Crossover generally biases the ITT results toward the null, potentially masking a true treatment effect. To address this, researchers can use Per-Protocol or As-Treated analyses, though these lose the benefit of randomization. Advanced causal inference methods, such as Rank Preserving Structural Failure Time (RPSFT) models or Inverse Probability of Treatment Weighting (IPTW), can be used to adjust for the effect of treatment switching while maintaining some rigor.

Journal Editor

Despite being an RCT, IABP-SHOCK II was open-label, and the primary endpoint was 30-day mortality. As an editor, how would you evaluate the risk of detection bias or performance bias in this study, and does the high rate of follow-up (near 100%) mitigate these concerns?

Key Response

While blinding providers to a physical pump is nearly impossible (preventing a double-blind design), 30-day mortality is a hard, objective endpoint unlikely to be influenced by observer bias. The primary threat to validity was performance bias (e.g., differences in other supportive care), but the near-complete follow-up and the pragmatic nature of the trial strengthen its external validity, making its results highly generalizable to standard clinical practice.

Guideline Committee

Based on the IABP-SHOCK II results, both the ESC and the AHA/ACC downgraded IABP recommendations. How do these findings specifically conflict with earlier guidelines, and what level of evidence is now assigned to the 'routine use' of IABP in AMI-complicated cardiogenic shock?

Key Response

Prior to this trial, IABP was a Class I recommendation based on pathophysiology and registry data. Following the trial, the ESC downgraded it to Class III (Routine use not recommended), and the AHA/ACC moved it to Class III: No Benefit (Level of Evidence: B-R). The committee's shift highlights the transition from eminence-based medicine to evidence-based medicine, prioritizing high-quality RCT data over physiological plausibility.

Clinical Landscape

Noteworthy Related Trials

1999

SHOCK Trial

n = 302 · NEJM

Tested

Early revascularization (via bypass or angioplasty)

Population

Patients with cardiogenic shock complicating acute myocardial infarction

Comparator

Initial medical stabilization

Endpoint

Mortality at 30 days

Key result: Early revascularization showed a significant survival benefit at 6 months compared to initial medical management.

2017

CULPRIT-SHOCK Trial

n = 683 · NEJM

Tested

Culprit-lesion-only percutaneous coronary intervention

Population

Patients with acute myocardial infarction, cardiogenic shock, and multivessel disease

Comparator

Immediate multivessel percutaneous coronary intervention

Endpoint

Composite of death or severe renal failure at 30 days

Key result: Culprit-lesion-only PCI resulted in a lower risk of death or renal replacement therapy compared to immediate multivessel PCI.

2018

DanShock Trial

n = 360 · JAMA

Tested

Impella CP microaxial flow pump

Population

Patients with myocardial infarction complicated by cardiogenic shock

Comparator

Standard care (including IABP)

Endpoint

All-cause mortality at 180 days

Key result: Mechanical circulatory support with Impella did not significantly reduce mortality compared to standard treatment.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis